Healthcare >> CEO Interviews >> January 22, 2001
HANS J. MDER, President and CEO of Procyon BioPharma Inc., has had
extensive experience with leading firms in the pharmaceutical industry
in Canada, the U.S.A and Europe. Prior to joining the company, Mr. Mder
was the Head of Global Marketing Services at the Head Office of Novartis
Pharma in Switzerland since 1998. Prior to this appointment, he directed
the merger of Ciba-Geigy and Sandoz in Canada and served as CEO of
Sandoz and then as President and CEO of the resulting company, Novartis
Pharmaceuticals Inc., Canada, with $300 million a year in annual
revenues and approximately 1,000 employees. While at Novartis, Mr. Mder
succeeded in attracting major research projects and investments to
Canada. At Sandoz, Mr. Mder also held senior marketing positions and
successfully launched several new products as well as innovative
marketing campaigns. Mr. Mder is a former member of the Board of
Canada's Research-Based Pharmaceutical Companies (formerly the
Pharmaceutical Manufacturers' Association of Canada) and as such, has
often spoken on the importance of global competition for the Canadian
biotechnology and pharmaceutical industries. Profile
the company?
Mr. Mder: Procyon BioPharma is basically an oncology biotechnology
company. We have four products; three of
